At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 25 enrolled
Drug / intervention
Zoledronic aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
In Brief
A Phase 3 clinical trial evaluating Zoledronic acid for Osteoporosis. Completed, enrolled 25 participants across 10 sites in 6 countries.
Detailed Summary
This 1-year open-label extension to CZOL446H2337 is designed to evaluate the safety and efficacy of zoledronic acid twice yearly in osteoporotic children treated with glucocorticoids.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesAustralia, Canada, Hungary, Russia, South Africa, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartOct 2010
Primary CompletionFeb 2019
TodayJul 2026
First PostedSep 9, 2010
Enrollment StartOct 25, 2010
Primary CompletionFeb 27, 2019
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 15.8 years ago
Interventions
Zoledronic aciddrug
intravenous infusion